Overview
Semax is a synthetic heptapeptide analog of the adrenocorticotropic hormone fragment ACTH(4-10), with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s, Semax has been approved in Russia as a prescription medication for the treatment of stroke, cognitive disorders, optic nerve disease, and peptic ulcers since 1994.
Unlike the parent ACTH molecule, Semax lacks hormonal (adrenocorticotropic) activity—it does not stimulate cortisol release or affect the HPA axis. Instead, its pharmacological effects are mediated through modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), as well as direct effects on monoaminergic neurotransmitter systems.
Semax has accumulated one of the largest evidence bases among nootropic peptides, with over 800 published studies spanning neuroprotection, cognitive enhancement, and immune modulation. Its clinical use in Russia for acute ischemic stroke has produced compelling data showing reduced infarct volume and improved neurological outcomes when administered within the first 6 hours of symptom onset.
This guide examines Semax's extensive research profile, its unique neurotrophic mechanism, clinical evidence from Russian and international studies, and its practical applications as a nootropic and neuroprotective agent.
Quick facts
- Mechanism
- ACTH(4-10) analog enhancing BDNF and neurotrophic signaling
- Primary use
- Neuroprotection & Cognitive Enhancement
- Evidence
- moderate
- FDA
- Not approved
- Route
- Intranasal spray (primary), subcutaneous injection
- Typical results
- Cognitive improvements within days; neuroprotective effects demonstrated in stroke recovery
Chemical information
Semax (C₃₇H₅₁N₉O₁₀S) is a cognition compound with a molecular weight of 813.92 g/mol. Its structural characteristics underpin its biological activity in cognitive function and neural health.
How Semax works
Semax's primary mechanism involves the upregulation of brain-derived neurotrophic factor (BDNF) and its receptor TrkB in the hippocampus, prefrontal cortex, and basal forebrain—brain regions critical for learning, memory, and executive function. BDNF is the brain's primary growth factor for neuronal survival, synaptic plasticity, and long-term potentiation (the cellular basis of memory formation).
Beyond BDNF, Semax stimulates the expression of nerve growth factor (NGF), glial cell line-derived neurotrophic factor (GDNF), and ciliary neurotrophic factor (CNTF). This broad neurotrophic factor activation promotes neuronal survival, axonal growth, and synaptic remodeling—processes collectively termed neuroplasticity. In stroke models, this neurotrophic support helps protect penumbral neurons from delayed cell death.
Semax modulates the dopaminergic and serotonergic systems by influencing the expression of tyrosine hydroxylase (the rate-limiting enzyme in dopamine synthesis) and tryptophan hydroxylase (rate-limiting for serotonin). These effects enhance catecholamine-dependent cognitive processes including attention, working memory, and motivation without the overstimulation associated with direct dopamine agonists.
The peptide also demonstrates significant anti-inflammatory and immunomodulatory properties. It inhibits the expression of pro-inflammatory cytokines (IL-1β, TNF-α) in activated microglia while promoting the expression of anti-inflammatory mediators. In the context of stroke, this neuroinflammatory modulation reduces secondary brain injury caused by the post-ischemic inflammatory cascade.
- BDNF upregulation: Increases brain-derived neurotrophic factor expression in hippocampus and cortex by 2–8 fold
- Neurotrophic cascade: Simultaneously activates NGF, GDNF, and CNTF expression for comprehensive neuroprotection
- Dopamine modulation: Enhances tyrosine hydroxylase expression for improved attention and working memory
- Anti-inflammatory: Suppresses microglial activation and pro-inflammatory cytokine release in CNS
- No HPA axis effects: Unlike parent ACTH, does not stimulate cortisol release or cause adrenal effects
- Epigenetic modulation: Alters expression of 24+ genes involved in neuronal survival and plasticity
Pharmacokinetics
| Parameter | Value | Significance |
|---|---|---|
| Bioavailability (intranasal) | ~60–70% | Good nasal absorption with direct CNS access |
| Half-life (plasma) | ~2–3 minutes | Rapid degradation but prolonged central effects lasting hours |
| CNS penetration | Confirmed via intranasal route | Nose-to-brain pathway bypasses blood-brain barrier |
| BDNF response onset | 30 minutes–4 hours | Rapid neurotrophic gene activation |
| Duration of cognitive effects | 4–8 hours | Supports 2–3 daily administrations |
| Steady-state benefits | Optimized after 7–14 days | Cumulative neuroplastic effects develop over 1–2 weeks |
Dosing & administration
Semax dosing varies by indication and individual factors. No FDA-approved dosing exists for this compound; protocols in the literature derive from limited clinical or preclinical data and practitioner experience.
Any use should be conducted under qualified medical supervision with appropriate monitoring of safety markers.
Important: These dosing ranges are not FDA-approved. Any use should be under qualified medical supervision.
Side effects & safety
Safety data for Semax is primarily derived from preclinical studies and limited human data. Long-term effects in humans remain incompletely characterized.
Common
- • Nasal irritation or dryness (intranasal route)
- • Mild headache (usually transient)
- • Slight dizziness during initial use
- • Mild restlessness or increased energy
- • Taste disturbance (metallic taste, rare)
Serious / potential risks
- • No serious adverse events reported in published clinical studies
- • Theoretical concern about neurotrophin modulation in brain tumors
- • Rare allergic reactions
- • Unknown interactions with Western psychiatric medications at high doses
Drug interactions
| Medication | Interaction | Recommendation |
|---|---|---|
| SSRIs / SNRIs | Semax modulates serotonin metabolism; potential additive effects | Monitor for serotonergic symptoms; generally considered safe but use caution |
| Stimulants (methylphenidate, amphetamines) | Both enhance catecholamine signaling; possible overstimulation | Reduce stimulant dose if combining; monitor for anxiety or insomnia |
| Anticoagulants | Semax affects fibrinolysis in stroke protocols | Use under neurologist supervision in stroke contexts |
| Benzodiazepines | Opposing mechanisms—Semax is activating while benzodiazepines are sedating | May reduce benzodiazepine sedation; no dangerous interaction reported |
| Selank | Complementary mechanisms; commonly co-administered in Russian practice | Well-established combination for combined nootropic and anxiolytic effects |
Storage & handling
Lyophilized (powder)
- • Store at -20°C to 4°C (freezer or refrigerator)
- • Protect from light and moisture
- • Stable for 12–24 months when stored properly
- • Keep in original sealed container until reconstitution
Reconstituted solution
- • Refrigerate at 2–8°C after reconstitution
- • Use bacteriostatic water for multi-dose reconstitution
- • Typical stability: 14–28 days refrigerated
- • Do not freeze reconstituted solution
Cost & availability
| Source | Cost | Notes |
|---|---|---|
| Russian pharmacies | $15–$30 per nasal spray bottle | Prescription medication in Russia; OTC in some CIS countries |
| Research peptide suppliers | $40–$80 per 5mg vial | Injectable form; third-party testing recommended |
| Compounding pharmacies | $100–$200 per month | Custom nasal spray formulations with prescription |
The bottom line
Semax is one of the most extensively studied nootropic peptides, with over 800 publications and approved clinical use in Russia for stroke and cognitive disorders. Its unique BDNF-enhancing mechanism provides both acute cognitive benefits and cumulative neuroprotective effects. While Western clinical trials are lacking, the volume of Russian clinical data is substantial.
Best for
- • Individuals seeking cognitive enhancement with neuroprotective properties
- • Researchers studying BDNF-mediated neuroplasticity and neuroprotection
- • Post-stroke recovery protocols under neurologist supervision
- • Those wanting a non-stimulant approach to attention and focus improvement
Not for
- • Individuals with active brain tumors
- • Those expecting immediate stimulant-like effects
- • Self-treatment of stroke or serious neurological conditions
- • Use without medical supervision in individuals on psychiatric medications
Related compounds
Frequently asked questions
References
- [1] Ashmarin IP, Nezavibatko VN, Levitskaya NG, et al.. Design and investigation of an ACTH 4-10 analog lacking D-amino acids and displaying nootropic and analgesic activity. Neurosci Res Commun (1995). doi: 10.1002/nrc.680170104
- [2] Dolotov OV, Karpenko EA, Inozemtseva LS, et al.. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res (2006). doi: 10.1016/j.brainres.2005.11.048 PMID: 16386717
- [3] Gusev EI, Skvortsova VI, Miasoedov NF, et al.. Effectiveness of Semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study). Zh Nevrol Psikhiatr Im S S Korsakova (1997). PMID: 9441510
- [4] Levitskaya NG, Sebentsova EA, Andreeva LA, et al.. The neuroprotective effects of Semax in conditions modeling clinical applications. Biol Bull (2020). doi: 10.1134/S1062359020010082
- [5] Filippenkov IB, Stavchansky VV, Denisova AE, et al.. Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia–Reperfusion in Rats. Genes (2020). doi: 10.3390/genes11060681 PMID: 32575702